Actively Recruiting
Italian Multicenter Observational Study Evaluating STRIDE Regimen for Advanced or Unresectable Hepatocellular Carcinoma Without Prior Systemic Treatment
Led by AstraZeneca · Updated on 2026-09-29
200
Participants Needed
24
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are observing patients with advanced or unresectable hepatocellular carcinoma HCC who have not received prior systemic treatment. The study evaluates how long it takes for clinical hepatic decompensation to occur, along with quality of life, effectiveness, and safety of the STRIDE regimen, which combines tremelimumab and durvalumab. This observational study is conducted across multiple centers in Italy and is sponsored by AstraZeneca. Patients receive the STRIDE treatment as part of routine clinical practice in Italy. This involves a single dose of tremelimumab 300 mg combined with durvalumab 1500 mg on the first day of the first cycle, followed by durvalumab alone every four weeks. The study observes this treatment over a period of up to 30 months, monitoring responses and safety outcomes. Participants are followed regularly for assessments including time to hepatic decompensation, overall survival, progression-free survival, tumor response, disease control, and safety measures. Data are collected from the start date until study completion, which may extend up to 33 months. Participants quality of life and treatment safety are also monitored throughout this period.
CONDITIONS
Brief Title
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
Research Team
A
AstraZeneca Clinical Study Information Center AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here